Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.

Cancers (Basel) · 2022 · PMC9558510 · PMID 36230489

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

One publication observed a nonsignificant trend between dabrafenib and hydroxy-dabrafenib exposure and pyrexia [ 24 ], whereas another study found no association [ 23 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.